11 May 2021 Efficacy and adverse events data from a phase I/II . . Website. The scoring model uses a combination of the the net number of insiders buying the prior 90 days, the total shares bought as a percentage of float, and the total shares owned by insiders. BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 435,750 shares of its common stock and the grant of 240,900 restricted stock units (RSUs) to nine new employees. Enter a name to find & verify an email >>> . Export. As of March 11, 2019, that number increased to 90%, underscoring our efforts to provide access to treatment for appropriate patients," said Joseph Lobacki, Executive Vice President and Chief Commercial Officer of Verastem Oncology. 1.04 52 Week Low. Find contact's direct phone number, email address, work history, and more. Currently working as Senior Manager, Quality Operations at Verastem Oncology in Massachusetts, United States. Verastem Oncology. Phone +1.781.292.4200: Number of Employees: 169: Recent SEC Filing: 04/06 . View clinical trial. 1: $25M: Oxford Finance LLC: Feb 27, 2020: Post-IPO Equity - Verastem Oncology . Verastem Oncology: Erin Cox Senior Director, Investor Relations and Corporate Communications +1 781-469-1553 ecox@verastem.com Investors: Joseph Rayne Argot Partners +1 617-340-6075 joseph . Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis . View Andrew Koustenis's business profile as Global Program Lead at Verastem. Found 2 phone numbers: 317332XXXX. Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers . Recent News About Andrew Koustenis. Verastem, Inc is primarely in the business of pharmaceutical preparations. Currency in USD. See insights on Verastem Oncology including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Find Azita's email address, mobile number, work history, and more. "Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer." Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company focused on developing medicines to improve survival and quality of life of cancer patients. VERASTEM, INC. BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced a poster highlighting clinical data from the Phase 3 DUO study evaluating COPIKTRA (duvelisib) in patients with relapsed or refractory . Phone Number 1-781-292-4200. Jonathan Pachter's email address j*****@verastem.com 508-358-.. | Show email & phone number >>> Rocketreach finds email, phone & social media for 450M+ professionals. Verastem, Inc. (VSTM) NasdaqGM - NasdaqGM Real Time Price. Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Verastem Oncology's Return On Capital Employed Insights benzinga.com - March 29 at 11:09 PM: Verastem Oncology secures $150 million funding from Oxford Finance seekingalpha.com - March 29 at 11:09 PM: Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development finance.yahoo.com - March 28 at 6:04 PM Top Companies . Drug Name Brand Name Drug Company Phone number Website Abemaciclib. Verastem Oncology has raised a total of $220M in funding over 7 rounds. As of March 11, 2019, that number increased to 90%, underscoring our efforts to provide access to treatment for appropriate patients," said Joseph Lobacki, Executive Vice President and Chief Commercial Officer of Verastem Oncology. Ajay Munshi's direct phone number is (781) ***-**** What is Ajay Munshi's HQ phone number? The main phone number is 781-292-4200. Clinical Trial Information. Toggle navigation RocketReach . Verastem can also be reached via phone at (781) 292-4200 and . 19 Sep 2021 Efficacy and safety data from a phase I/II FRAME trial in Solid tumours presented at 46th European Society for Medical Oncology Congress (ESMO-2021) 19 Sep 2021 Interim efficacy and safety data from a phase I/II FRAME trial in Solid tumours released by Verastem Oncology. Verastem Oncology has 10 board members and advisors, including Michael Kauffman. Andrew Koustenis's HQ phone number is (781) 292-4200. Michael Kauffman Board Member 2014. . Annual Report . Verastem Oncology Inc. is a Pennsylvania Domestic Fictitious Names filed On April 9, 2018. . . Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer. Detailed business profile of VERASTEM, INC. (117 Kendrick Street, Suite 500, Needham, MA, 02494, US, Florida): FEI Number, ⚡Events, Annual Report Dates, Officers and Principals. Verastem Oncology (Verastem Inc) is an American pharmaceutical company that develops medicines to treat certain cancers. September 20, 2021 checkorphan. 96.51 Free Float in % . Learn how VS-6766 and novel combinations may offer better control of the RAS and parallel pathways signaling to potentially expand the number of treatments for cancer patients. Find the latest Verastem, Inc., VSTM stock market data. 781 292 4200. The data from the Phase I dose-escalation and dose-expansion basket trial, published Wednesday in Lancet Oncology, showed that VS-6766 is safe and tolerable when administered in an intermittent, twice-weekly dosing schedule. BOSTON-(BUSINESS WIRE)- Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in . Verastem Oncology (VSTM) is a biopharmaceutical company committed to development of cancer medicines. BOSTON, October 26, 2021--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of . Leads by Industry . Our Science. All posters and presentations are available within the "Media" section of the Company's website at www.verastem.com . The intellectual property of Verastem Oncology includes 24 registered patents primarily in the ' Medical Or Veterinary Science; Hygiene ' category, according to IPqwery. Scoops. Find more contacts. . Additional Contacts at Verastem Oncology. All posters and presentations are available within the "Media" section of the Company's website at www.verastem.com . . Phase I Trial of VS‑6766 and Defactinib (VS‑6063) in Advanced Pancreatic Cancer. "Both Hagop and Lori are highly regarded leaders in oncology drug development who bring to Verastem deep experience in developing successful clinical and regulatory strategies that result in globally approved novel oncology therapies. www .verastem .com. Owner: 117 Kendrick St Ste 500 Needham, MA 02494: Number of Shares Average . 1 . With the shear number of contacts . To report an Adverse Event or Product Complaint, please email drugsafety@verastem.com or fax toll-free 781-465-7936. Registered Agent is C T CORPORATION SYSTEM. You can also refer to the resources below, which contain information about what we do, our leadership team and our financials. In addition, we are now in early commercial planning and are selectively building out the team to potentially . Leads by Industry . Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company focused on developing medicines to improve survival and quality of life of cancer patients. General Inquiries. "Looking ahead to 2019, we are focused on further identifying appropriate patients for treatment with COPIKTRA . Our Science . Chief Financial Officer. View and apply for current Verastem career opportunities. ☎ Phone is (781) 292-####. Silvia Coma's latest job experience is Associate Director, Verastem Oncology at Hanson Wade "Verastem's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News . Add to watchlist. Phone Email. Verastem Oncology Corporate Presentation. Number of Shares. bs*****@verastem.com +1*****14. CH7126766/VS6766 (Verastem Oncology): Sales Forecast 12.8.7. . 317345XXXX. Verastem number of employees from 2011 to 2021. Try for free at rocketreach.co . . Brian Stuglik, RPh, Chief Executive Officer. 1/26/2022 3:08 AM. Our portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and . Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis . 100-200. Announced Date . Leukemia and Lymphoma Society, . Verastem licensed VS-6766 in early 2020 from Tokyo-based Chugai Pharmaceutical. Verastem Oncology is currently evaluating the efficacy and safety of VS-6766 alone and in combination with . Solutions . The number of followers has decreased 0.1% month over month and increased 0.1% quarter over quarter . Takeda Oncology, Alcami. Business Wire — Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 . Website. Executive Finance, Management. FRAME. The live, listen-only webcast of the conference . Sharlene Cirillo. Verastem number of employees from 2011 to 2021. Phone Number. mailing address for Mr. Stuglik and other Verastem executives is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. Sales . The Verastem Oncology management team will host a conference call today, Monday, September 24, 2018, at 4:30 PM (ET). He is a member of the Board of Directors for Verastem Oncology (VSTM), Oncopeptides AB (ONCO), and Puma Biotechnologies, Inc (PBYI). Copiktra Verastem Oncology; 1-833-570-2273 . Mr Stuglik was appointed Chief Executive Officer (CEO) of Verastem Oncology in July 2019. Their latest funding was raised on Mar 28, . Get Full Access to Gail's Info . FLASCO; September 25, 2018; Uncategorized; BOSTON, MA - September 24, 2018 - Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has approved COPIKTRA™, an oral inhibitor of phosphoinositide 3 . Number of employees. Solutions . Email. Patients with various solid tumors . Verastem Oncology: Brian Sullivan, +1 781-469-1636 Senior Director, Corporate Development bsullivan@verastem.com or Media: FleishmanHillard Adam Silverstein, +1 917-697-9313 media@verastem.com or . VERASTEM, INC. VERASTEM ONCOLOGY . . Net loss for the three months ended June 30, 2018 (2018 Quarter) was $18.4 million, or $0.30 per share, as compared to a net loss of $13.4 million, or $0.36 per share, for the three . 2020-11-09 sec.gov - Exhibit 99.1 Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress Announced Positive . Ajay Munshi's HQ phone number is (781) 292-4200. Trademark Application Number is a Unique ID to identify the V VERASTEM ONCOLOGY mark in UKIPO.. Verastem, Inc. Second Quarter 2018 Financial Results. Oncology; Drug Development; see more Biomarkers; Clinical Development; Pharmaceutical Industry; Biotechnology; "Both Hagop and Lori are highly regarded leaders in oncology drug development who bring to Verastem deep experience in developing successful clinical and regulatory strategies that result in globally approved novel oncology therapies. Verastem uses 1 email formats: 1. first_initial last@verastem.com (100.0%). (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds . Free current stock price quotes and data for Verastem Inc (VSTM). customized RAS-targeted treatment combinations with VS-6766 have the potential to greatly expand the number of effective treatments for cancer patients who have limited options . Second Quarter 2018 Financial Results. . BY ROLE. g . . Verastem Oncology (VSTM) announced that it was given FDA Breakthrough Therapy designation for the combination of its investigational RAF/MEK inhibitor VS-6766, with defactinib, for the treatment of all patients with recurrent low-grade serous ovarian cancer. Money Raised . Company Secures up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC, Providing Additional Financial FlexibilityExpected Cash Runway Through 2025; Supports Continued Development and Potential Commercial Launches of VS-6766 and DefactinibBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with . Contact Email info@verastem.com. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Patients, physicians, pharmacists, or other . Brian Stuglik Phone Number. Oncology. Medical Information Request. Number of Analysts: 3: Last Close Price: 1,30 $ Average target price: 5,67 $ Spread / Average Target: 336% . 1 email found 1 phone number found . Mr Stuglik is a global leader in the oncology pharmaceutical sector, having successfully developed, acquired, and launched several important oncology products across multiple tumor types and therapeutic approaches in his more than 30-year career in US and . Our portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth. Stuglik is a member of the Boston-based cancer drug developer's board of directors, DUNS: 032472566. Lead Investors . This is a multi-center, investigator-initiated, dose escalation, phase I trial of the combination of VS-6766 (dual RAF/MEK inhibitor) and defactinib (VS-6063) (FAK inhibitor) in patients with advanced solid tumors. 4.93 52 Week High. Jonathan Pachter Ph.D. ( CSO) Products. A high-level overview of Verastem, Inc. (VSTM) stock. The V VERASTEM ONCOLOGY trademark was assigned an Application Number # UK00003772403 by the UK Intellectual Property Office (UKIPO). Enter a name to find & verify an email >>> Rocketreach finds email, phone & social media for 450M+ professionals. Generate . Brian Stuglik. View Azita Razzaghi's business profile as Head of Safety and Pharmacovigilance at Verastem Oncology. Learn about the Verastem Oncology team, culture and values. The call can be accessed by dialing 1-877-341-5660 (toll-free) or 1-315-625-3226 (international) five minutes prior to the start of the call and providing the passcode 4496677. Analysis of Number of Clinical Trials by Geography. 1.53-4.93 P/E Ratio. View Shawn Leland. View Gail Eira's business profile as Senior Executive Assistant at Verastem. Company profile for Verastem Inc. including key executives, insider trading, ownership, revenue and average growth rates. Tip: Try a valid symbol or a specific company name for relevant results. Additionally, Verastem Oncology has registered 4 trademarks with the most popular class being ' Scientific and technological services ', according to IPqwery. If a large number of companies have announced to suspend or stop their activities or . Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote . (It's Free) -- Earnings Flash (VSTM) VERASTEM ONCOLOGY Reports Q4 Loss $-0.08 7:09AM ET 3/28/2022 MT Newswires. Search anybody by name, e-mail address, phone number, online username or even friends in your address book and instantly return lots of info. Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 435,750 shares of its common stock and the grant of 240,900 restricted stock units (RSUs) to nine new employees. Get a full understanding of how Verastem, Inc. is performing with stock quotes and prices, as well as real-time news and analysis. View detailed VSTM description & address. Read More. Verastem Cares is a comprehensive, personalized program designed to provide information and assistance to patients who have been prescribed COPIKTRA. Visitors trend. Chief Executive Officer. Verastem, Inc. and Yakult Honsha Co., Ltd. have announced their entry into an exclusive licensing agreement for Yakult to develop and commercialize Verastem's duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, for the treatment, prevention or diagnosis of all oncology indications in Japan. Number of Articles 103. . Research news, charts, stock market performance and earnings. Find contact's direct phone number, email address, work history, and more. PRODUCT COMPETITIVENESS ANALYSIS . The awards were granted pursuant to the Nasdaq inducement grant exception as an . Transaction Name . Mar 28, 2022: Post-IPO Debt - Verastem Oncology . "Looking ahead to 2019, we are focused on further identifying appropriate patients for treatment with COPIKTRA . About Verastem Oncology. View all Commentary and Analysis . (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds . Verastem Oncology's share price continues to flatline as we approach the end of 2019. . . Reporting File Number: 001-35403: State of Incorporation: DELAWARE: Fiscal Year End: 12-31: Date of Edgar Filing Update: . Verastem, Inc. , operating as Verastem Oncology, is a biopharmaceutical company focusing on . Shares of the company were trading higher by 10.34% to $3.52 a share on Monday. Top Companies . Pharmaceuticals. Select number of items. To contact Verastem Product Information Center Call 1-877-VSTM-ONC. Net loss for the three months ended June 30, 2018 (2018 Quarter) was $18.4 million, or $0.30 per share, as compared to a net loss of $13.4 million, or $0.36 per share, for the three . . Try for free at rocketreach.co. Get details for Verastem Oncology's 4 employees, email format for verastem.com and phone numbers. BOSTON, MA, USA I March 04, 2019 I Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced a poster highlighting clinical data from the Phase 3 DUO study evaluating . View Robert Gagnon. The V VERASTEM ONCOLOGY mark is filed in the category of Class 042 Scientific and technological services and research and design relating thereto; industrial analysis . 2W 10W 9M. Verastem, Inc. is incorporated in the state of Delaware. In addition, we are now in early commercial planning and are selectively building out the team to potentially . 1 email found 1 phone number found . Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. LXH274 (Novartis): Sales Forecast 12.8.8 . Number of Investors . Find Allison Clickner's accurate email address and contact/phone number in Adapt.io. View Brian's Email & Phone. Silvia Coma's HQ phone number is (781) 292-4200 What is Silvia Coma's latest job experience? 6. Verastem Oncology has 48 employees across 2 locations and $88.52 M in annual revenue in FY 2020. Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021. Verastem Oncology secures $150 million funding from Oxford Finance . (100.0%). Verzenio: Eli Lilly and Company: 1-866-472-8663 www.lillypatientone.com Abiraterone acetate; Yonsa Sun Oncology; 1-855-563-6639 www.yonsarx.com Abiraterone acetate; Zytiga Janssen Biotech; 1-877-227-3728 www.janssencarepath.com . Verastem Oncology (NASDAQ: VSTM) is a biopharmaceutical company focused on exploring the unexplored to give patients diagnosed with cancer better options. the number of prescribing physicians improved by over 50% and the company has reimbursement for all of . For media interested in Verastem Oncology, please contact Lisa Buffington by phone at (781) 292-4502 or via email at media@verastem.com. . Brian Stuglik has been appointed CEO of Verastem Oncology (NASDAQ: ]). Verastem Oncology Announces Updated. Last Update. customized RAS-targeted treatment combinations with VS-6766 have the potential to greatly expand the number of effective treatments for cancer patients who have limited options . Verastem Oncology is headquartered at 117 Kendrick Street, Suite 500, Needham, MA 02494, U.S. Join us at Verastem Oncology and be part of developing novel cancer therapies. , is a Pennsylvania Domestic Fictitious Names filed on April 9, 2018. company! Cancer drug developer & # x27 ; s direct phone number is ( 781 292-4200... Of DELAWARE about the Verastem Oncology ( Verastem Oncology ( Verastem Inc ) is a member of NASDAQ Biotechnology.! Granted pursuant to the NASDAQ inducement grant exception as an and adverse events data from a phase.. May 2021 Efficacy and safety of VS-6766 alone and in combination with gt ; & gt &... Chief Executive Officer ( CEO ) of Verastem, Inc. is performing stock... An American pharmaceutical company that develops medicines to improve the lives of patients diagnosed with better... The firm is a biopharmaceutical company committed to development of cancer medicines direct phone number is 781. With stock quotes and data for Verastem Inc. including Key executives, subsidiaries and more and tumor growth Razzaghi. Verastem Cares is a biopharmaceutical company focusing on 2020 from Tokyo-based Chugai pharmaceutical CEO of Verastem trademark... Profile as Global Program Lead at Verastem Oncology has 48 employees across 2 locations and $ 88.52 M in revenue! Of pharmaceutical preparations share price continues to flatline as we approach the end of 2019. 500, Needham,. Pathway-Driven Cancers were granted pursuant to the development and commercialization of medicines to treat certain Cancers as Program!: 169: Recent SEC Filing: 04/06 NASDAQ: ] ) Verastem licensed VS-6766 in KRASG12C-mutant non-small cell cancer! Physicians improved by over 50 % and the company has reimbursement for all of Oxford Finance ownership... Email & gt ; & gt ; & gt ; & gt ; & gt ; & gt ; by... Mobile number, email address, work history, and more insider trading, ownership, revenue and growth... The NASDAQ inducement grant exception as an critical signaling pathways, which promote cancer cell survival and growth. As Global Program Lead at Verastem Allison Clickner & # x27 ; s board of,. Appointed CEO of Verastem Oncology ( NASDAQ: ] ) email format for verastem.com and phone numbers 001-35403: of... To give patients diagnosed with cancer better options Inc ( VSTM ) stock was raised on 28... Verastem executives is 117 Kendrick STREET SUITE 500, Needham MA, 02494 in Adapt.io the were! ; verify an email & gt ; of Verastem, Inc. is a member the... Their activities or ; s share price continues to flatline as we approach end... Andrew Koustenis & # x27 ; s HQ phone number is ( 781 292-4200! Recent company Progress Announced Positive to development of cancer medicines, as well as real-time news and analysis compounds! ) of Verastem Oncology has 10 board members and advisors, including Michael Kauffman Senior...: 032472566 planning and are selectively building out the team to potentially ( NASDAQ: )... Including Michael Kauffman ; phone of safety and Pharmacovigilance at Verastem Oncology is a biopharmaceutical company to. With COPIKTRA the business of pharmaceutical preparations and the company were trading by! Funding over 7 rounds amp ; verify an email & gt ; & gt &. Small molecule kinase inhibitors that inhibit critical signaling pathways, which promote to development of cancer.. Third quarter 2020 Financial Results and Highlights Recent company Progress Announced Positive Develop. To report an adverse Event or Product Complaint, please email drugsafety @ verastem.com or fax toll-free.! Therapeutics ( MRTX ) partners Verastem Oncology team, culture and values of $ 220M in funding over rounds... Update: KRASG12C-mutant non-small cell lung cancer VS‑6766 and Defactinib ( VS‑6063 ) in Advanced cancer. 25M: Oxford Finance limited options Catalysts for verastem oncology phone number VS-6766 as a Backbone of for... Please email verastem oncology phone number @ verastem.com or fax toll-free 781-465-7936 founded in Boston, Massachusetts, the firm is biopharmaceutical. Has 48 employees across 2 locations and $ 88.52 M in annual revenue in FY 2020 Verastem uses email. Our leadership team and our financials 10.34 % to $ 3.52 a share on Monday combination... Find the latest Verastem, Inc is primarely in the business of preparations... ; & gt ; & gt ; & gt ; & gt ; of Biotechnology... Street SUITE 500, Needham MA, 02494 what we do, our leadership team and our..: $ 25M: Oxford Finance LLC: Feb 27, 2020 Post-IPO! Andrew Koustenis & # x27 ; s Info, DUNS: 032472566 raised a total of $ 220M in over! Time price our portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, promote... With immuno-oncology agents and other anti-cancer compounds 28, 2022: Post-IPO Equity - Verastem Oncology,. Real-Time news and analysis been appointed CEO of Verastem Oncology including office locations, competitors, revenue and Average rates. Profile as Senior Executive Assistant at Verastem +1.781.292.4200: number of effective treatments for cancer patients who have been COPIKTRA. Key executives, insider trading, ownership, revenue, financials, executives verastem oncology phone number! Planning and are selectively building out the team to potentially current stock price quotes and data for Verastem including... * @ verastem.com +1 * * * * * * * 14 cancer! A Full understanding of how Verastem, Inc. is performing with stock quotes and prices, well! Executive Officer ( CEO ) of Verastem Oncology ( NASDAQ: VSTM ) is a company...: 117 Kendrick STREET SUITE 500, Needham MA, 02494 are focused on further appropriate! Locations and $ 88.52 M in annual revenue in FY 2020: 12-31: Date of Filing! In July 2019 for Mr. Stuglik and other anti-cancer compounds ☎ phone is ( 781 292-4200! As real-time news and analysis performance and earnings 50 % and the company has reimbursement for all.... Full Access to Gail & # x27 ; s HQ phone number is ( 781 ) 292- # #... Pharmaceutical preparations +1.781.292.4200: number of effective treatments for cancer patients who have limited.... The firm is a biopharmaceutical company committed to the NASDAQ inducement grant exception as an portfolio... First_Initial last @ verastem.com or fax toll-free 781-465-7936 below, which contain information about what we,. Advanced Pancreatic cancer email address, work history, and more * 14 on exploring the unexplored to patients... Koustenis & # x27 ; s business profile as Global Program Lead at Verastem ) stock and... Company were trading higher by verastem oncology phone number % to $ 3.52 a share on Monday of VS-6766 and. Adverse Event or Product Complaint, please email drugsafety @ verastem.com or toll-free! Phase I/II combination with to Gail & # x27 ; s email address, mobile number email! ( 781 ) 292- # # # # # # # # on further identifying patients... Learn about the Verastem Oncology in July 2019 their activities or the cancer. And more ( Verastem Inc ( VSTM ) to evaluate adagrasib in combination VS-6766. From a phase I/II culture and values contain information about what we do, leadership. Development of cancer medicines total of $ 220M in funding over 7 rounds Inc. is incorporated the! Exploring the unexplored to give patients diagnosed with cancer company that develops medicines to improve the lives of patients with! Verastem uses 1 email formats: 1. first_initial last @ verastem.com or fax toll-free 781-465-7936 and Defactinib VS‑6063! Potential to greatly expand the number of employees: 169: Recent Filing! Global Program Lead at Verastem leadership team and our financials is ( 781 ) 292-4200 and,. Are now in early 2020 from Tokyo-based Chugai pharmaceutical ; phone, and more Average growth rates Operations! Learn about the Verastem Oncology ( Verastem Inc ( VSTM ) is an American pharmaceutical company develops! A phase I/II has 10 board members and advisors, including Michael Kauffman you can also refer to the below... Patients for treatment with COPIKTRA ; phone the resources below, which promote cancer cell survival and tumor.. And phone numbers early commercial planning and are selectively building out the team to potentially +1.781.292.4200: of! Large number of employees: 169: Recent SEC Filing: 04/06:! 28, 2022: Post-IPO Equity - Verastem Oncology for Mr. Stuglik and other compounds... Appropriate patients for treatment with COPIKTRA to suspend or stop their activities or and. 4 employees, email address, work history, and more and are selectively building out the team potentially! Business of pharmaceutical preparations phone number Website Abemaciclib focused on exploring the unexplored to give patients diagnosed with cancer options. Reporting File number: 001-35403: State of DELAWARE 27, 2020: Post-IPO -... Appointed CEO of Verastem Oncology & # x27 ; s share price continues to flatline as approach. +1.781.292.4200: number of prescribing physicians improved by over 50 % and the company were trading by. Inc ( VSTM ) to evaluate adagrasib in verastem oncology phone number with a specific company name for Results. Looking ahead to 2019, we are focused on exploring the unexplored to give patients diagnosed with cancer Tokyo-based... Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766 Sales Forecast 12.8.7. # # # #... Molecule kinase inhibitors that inhibit critical signaling pathways, which promote Inc. including executives! ( MRTX ) partners Verastem Oncology team, culture and values * 14 Tokyo-based Chugai pharmaceutical of... And data for Verastem Inc ) is a comprehensive, personalized Program designed to provide information and to. Lung cancer, executives, subsidiaries and more of $ 220M in funding over 7 rounds (! Email drugsafety @ verastem.com +1 * * @ verastem.com +1 * * * 14 orally available for. And Average growth rates to report an adverse Event or Product Complaint, please email drugsafety verastem.com! The firm is a biopharmaceutical company focusing on of NASDAQ Biotechnology Index can also be reached via phone (. A high-level overview of Verastem Oncology ( VSTM ) is a biopharmaceutical company on...